<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="579">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>24/10/2005</approvaldate>
  <actrnumber>ACTRN12605000687695</actrnumber>
  <trial_identification>
    <studytitle>A proof of concept, single centre, monotherapy, dose-ranging trial to evaluate the efficacy and tolerability of CB0011 at 0,7.5, 15, 30 and 45mg in Obstructive Sleep Apnea.</studytitle>
    <scientifictitle>A proof of concept, single centre, monotherapy, dose-ranging trial to evaluate the efficacy and tolerability of CB0011 at 0,7.5, 15, 30 and 45mg in Obstructive Sleep Apnea.</scientifictitle>
    <utrn />
    <trialacronym>POC001</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive Sleep Apnea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A six week cross-over design study in patients with Obstructive Sleep Apnea (OSA). Patients (n=42) will be randomly enrolled into one of six dose sequence groups at an equivalent ratio.</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in Obstructive Sleep Apnea as measured by the patient apnea hypopnea index score (AHI).</outcome>
      <timepoint>Parameters measured at baseline, week two, week four and week six (or early termination) by overnight polysomnography and between three and five nights per week by patients utilising an ambulatory home monitoring device.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in Obstructive Sleep Apnea as measured by the respiratory disturbance index (RDI).</outcome>
      <timepoint>Parameters measured at baseline, week two, week four and week six (or early termination) by overnight polysomnography and between three and five nights per week by patients utilising an ambulatory home monitoring device.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in Obstructive Sleep Apnea as measured by oxygen desaturation index (ODI).</outcome>
      <timepoint>Parameters measured at baseline, week two, week four and week six (or early termination) by overnight polysomnography and between three and five nights per week by patients utilising an ambulatory home monitoring device.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in daytime sedation, sleep quality, mood, fatigue and weight.</outcome>
      <timepoint>Measured at baseline, week two, week four and week six.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Early termination and quality of life.</outcome>
      <timepoint>Measured at baseline and week six or early termination.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects must have a current diagnosis of Obstructive Sleep Apnea, have an apnea-hypopnea index (AHI) of between 10-40 (using a strict definition of hypopnea), with a calculated BMI equal or less than 40 at the time of study entry.</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation at pharmacy</concealment>
    <sequence>block allocation to dose sequence and customised computer sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>4/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>42</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cypress Bioscience Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Cypress Biosince Inc.</fundingname>
      <fundingaddress>x</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress>x</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Woolcock Institute of Medical Research</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Ron Grunstein</name>
      <address>Sleep and Circadian Research Group
Woolcock Institute of Medical Research
Level 6 Building F
88 Mallett Street
Camperdown NSW 2050</address>
      <phone>+61 2 95158630</phone>
      <fax>+61 2 95157196</fax>
      <email>rrg@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Renee Crompton</name>
      <address>Sleep and Circadian Research Group
Woolcock Institute of Medical Research
Royal Prince Alfred Hospital
Page 7
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95157763</phone>
      <fax>+61 2 95575059</fax>
      <email>reneec@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>